Abstract
Introduction: Type 2 diabetes mellitus, a metabolic disease with increasing incidence, is one of the most important cardiovascular risk factors. Insulin resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Metformin and the thiazolidinediones, pioglitazone and rosiglitazone, are insulin-sensitizing agents available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of both metformin and pioglitazone in reducing cardiovascular morbidity and mortality. The fixed-dose combination of metformin and pioglitazone appears to be a good option for treating diabetes in insulin-resistant patients. Aims: The purpose of this article is to review the place in therapy of a fixed-dose combination of pioglitazone and metformin in the management of patients with type 2 diabetes. Evidence review: The current evidence suggests that combined therapy may help to achieve the recommended goals in the management of diabetes. A fixed-dose formulation of pioglitazone and metformin may provide advantages in terms of glycemic control and other cardiovascular risk factors frequently associated with diabetes. Place in therapy: The current evidence shows that a fixed-dose formulation of pioglitazone and metformin offers an effective option for the management of patients with type 2 diabetes when monotherapy fails in the achievement of the recommended standards of care.
Original language | English |
---|---|
Pages (from-to) | 189-198 |
Number of pages | 10 |
Journal | Core Evidence |
Volume | 2 |
Issue number | 3 |
Publication status | Published - 2008 |
Keywords
- Cardiovascular risk factors
- Diabetes
- Metformin
- Outcomes
- Pioglitazone
ASJC Scopus subject areas
- Medicine(all)
- Reviews and References, Medical
- Pharmacology